ADVM
Price
$2.69
Change
+$0.22 (+8.91%)
Updated
Aug 13, 04:59 PM (EDT)
Capitalization
46.59M
DNLI
Price
$14.82
Change
+$1.60 (+12.10%)
Updated
Aug 13, 04:59 PM (EDT)
Capitalization
1.92B
78 days until earnings call
Interact to see
Advertisement

ADVM vs DNLI

Header iconADVM vs DNLI Comparison
Open Charts ADVM vs DNLIBanner chart's image
Adverum Biotechnologies
Price$2.69
Change+$0.22 (+8.91%)
Volume$200
Capitalization46.59M
Denali Therapeutics
Price$14.82
Change+$1.60 (+12.10%)
Volume$68.91K
Capitalization1.92B
ADVM vs DNLI Comparison Chart in %
Loading...
ADVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADVM vs. DNLI commentary
Aug 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADVM is a Hold and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 14, 2025
Stock price -- (ADVM: $2.47 vs. DNLI: $13.22)
Brand notoriety: ADVM and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADVM: 44% vs. DNLI: 128%
Market capitalization -- ADVM: $46.59M vs. DNLI: $1.92B
ADVM [@Biotechnology] is valued at $46.59M. DNLI’s [@Biotechnology] market capitalization is $1.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Biotechnology] industry is $1.79B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADVM’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ADVM’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ADVM is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADVM’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 2 bullish TA indicator(s).

  • ADVM’s TA Score: 4 bullish, 5 bearish.
  • DNLI’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, ADVM is a better buy in the short-term than DNLI.

Price Growth

ADVM (@Biotechnology) experienced а -1.98% price change this week, while DNLI (@Biotechnology) price change was -7.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.47%. For the same industry, the average monthly price growth was +20.22%, and the average quarterly price growth was +20.09%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+11.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.92B) has a higher market cap than ADVM($46.6M). DNLI YTD gains are higher at: -35.132 vs. ADVM (-47.109). ADVM has higher annual earnings (EBITDA): -154.84M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. ADVM (83.1M). DNLI has less debt than ADVM: DNLI (48.6M) vs ADVM (93.2M). ADVM has higher revenues than DNLI: ADVM (1M) vs DNLI (0).
ADVMDNLIADVM / DNLI
Capitalization46.6M1.92B2%
EBITDA-154.84M-505.16M31%
Gain YTD-47.109-35.132134%
P/E RatioN/AN/A-
Revenue1M0-
Total Cash83.1M818M10%
Total Debt93.2M48.6M192%
FUNDAMENTALS RATINGS
ADVM vs DNLI: Fundamental Ratings
ADVM
DNLI
OUTLOOK RATING
1..100
561
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
6581
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5032

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADVM's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that ADVM’s stock grew somewhat faster than DNLI’s over the last 12 months.

ADVM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that ADVM’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (96) in the Biotechnology industry is in the same range as ADVM (99). This means that DNLI’s stock grew similarly to ADVM’s over the last 12 months.

ADVM's Price Growth Rating (65) in the Biotechnology industry is in the same range as DNLI (81). This means that ADVM’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ADVM (100). This means that DNLI’s stock grew similarly to ADVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADVMDNLI
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 14 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ADVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TLGAX14.00N/A
N/A
Timothy Plan Large/Mid Cap Growth A
HIMCX29.05N/A
N/A
Hartford MidCap HLS IA
ACEIX10.91N/A
N/A
Invesco Equity and Income A
LMPOX33.31N/A
N/A
ClearBridge Small Cap Growth R
ILVBX10.36N/A
N/A
Columbia Integrated Large Cap Val A

ADVM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADVM has been loosely correlated with XENE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ADVM jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADVM
1D Price
Change %
ADVM100%
+10.27%
XENE - ADVM
49%
Loosely correlated
+5.51%
RGNX - ADVM
47%
Loosely correlated
+8.58%
DNLI - ADVM
47%
Loosely correlated
-5.03%
OCUL - ADVM
46%
Loosely correlated
-0.68%
CCCC - ADVM
46%
Loosely correlated
-7.44%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-5.03%
NRIX - DNLI
58%
Loosely correlated
+3.83%
BEAM - DNLI
58%
Loosely correlated
-1.78%
ARWR - DNLI
56%
Loosely correlated
+3.43%
OCUL - DNLI
55%
Loosely correlated
-0.68%
RGNX - DNLI
54%
Loosely correlated
+8.58%
More